The use of the rat model for Ang II-induced kidney damage allows the exploration of the cellular mechanisms involved in the therapeutic effects of SGLT inhibition and AT1 receptor blockade as mono- or combination therapy, supporting a clinical use of either therapy. This evidence concerns the gene AGTR1 and Nephropathy.